Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0000919574-18-000982
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-02-09 18:31:41
Reporting Period:
2018-02-02
Accepted Time:
2018-02-09 18:31:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1267602 Alimera Sciences Inc ALIM Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1601086 Armistice Capital, Llc 510 Madison Avenue
22Nd Floor
New York NY 10022
No No Yes No
1633584 Ltd. Fund Master Capital Armistice C/o Dms Corporate Services Ltd.
20 Genesis Close, P.o. Box 314
Grand Cayman E9 KY1-1104
No No Yes No
1706140 Steven Boyd C/o Armistice Capital, Llc
510 Madison Avenue, 22Nd Floor
New York NY 10022
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-02-02 8,000 $1.16 6,924,000 No 4 P Direct
Common Stock Acquisiton 2018-02-02 0 $0.00 6,924,000 No 4 P Indirect See Footnote
Common Stock Acquisiton 2018-02-02 0 $0.00 6,924,000 No 4 P Indirect See Footnote
Common Stock Acquisiton 2018-02-05 4,000 $1.14 6,928,000 No 4 P Direct
Common Stock Acquisiton 2018-02-05 0 $0.00 6,928,000 No 4 P Indirect See Footnote
Common Stock Acquisiton 2018-02-05 0 $0.00 6,928,000 No 4 P Indirect See Footnote
Common Stock Acquisiton 2018-02-06 8,000 $1.12 6,936,000 No 4 P Direct
Common Stock Acquisiton 2018-02-06 0 $0.00 6,936,000 No 4 P Indirect See Footnote
Common Stock Acquisiton 2018-02-06 0 $0.00 6,936,000 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Direct
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Direct
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Footnotes
  1. The reported securities are directly owned by Armistice Capital Master Fund, Ltd.
  2. The reported securities are directly owned by Armistice Capital Master Fund, Ltd., a Cayman Islands corporation, and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund, Ltd. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital, LLC and Director of Armistice Capital Master Fund, Ltd. Armistice Capital, LLC and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.